Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib plus XELOX as Neoadjuvant Therapy in Gastric Cancer
NCT03229096Phase 2Unknown
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Feb 2017
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Rivoceranib in gastric cancer (GC), sponsored by Zhongshan Hospital, Fudan University. Primary endpoint: Objective Response Rate at 3 months. Status: unknown.
02
Drugs
Rivoceranib
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT03229096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03229096.